Safety Evaluation of Tradipitant Dosing in 4-Organ Human-on-a-Chip System to be Presented at SOT 2026
A 4-organHuman-on-a-Chip® model was used to study the safety profile of tradipitant, the results supported its recent approval for motion sickness.
Presentation Details
Safety Evaluation of Supraphysiological Tradipitant Dosing under Differential Liver Metabolism
Presented by: Jessie Carlin, Ph.D., Vanda Pharmaceuticals
Monday, March 23, 2026, 4:15 PM PDT
Ballroom 6C
Learn more and discover how we can advance your pipeline faster and more efficiently
Explore Other Hesperos News
Hesperos Awarded NIH Phase II Grant to Advance Malaria-on-a-Chip Platform for Novel Therapeutics
Funding from the National Institute of Allergy and Infectious Diseases (NIAID) will expand Hesperos’ physiologically relevant Malaria-on-a-Chip model to bridge critical translational gaps and accelerate the evaluation of next-generation antimalarial therapies. ORLANDO, FLORIDA, 22 October 2026: … Read More
Hesperos and UCF Showcase First-of-its-Kind Human-on-a-Chip® Comorbidity Model to Accelerate Drug Discovery for Aging Populations
Hesperos and UCF publish new study in Alzheimer’s and Dementia demonstrating peripheral neuromuscular pathology is NOT CNS dependent in Alzheimer’s Disease
Advancing Human-Relevant Science: Hesperos Featured in ‘The New Gold Standard’ Documentary
The Hesperos team recently gathered for a private screening of the upcoming feature documentary, The New Gold Standard: Cutting Edge Science That’s Replacing Animal Testing. As pioneers in human-on-a-chip technology, our routine focus centers on the … Read More